Vcanbio Cell & Gene Engineering Corp., Ltd. (600645) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Vcanbio Cell & Gene Engineering Corp., Ltd.

Why is Vcanbio Cell & Gene Engineering Corp., Ltd. ?

Poor Management Efficiency with a low ROCE of 4.85%

The company has been able to generate a Return on Capital Employed (avg) of 4.85% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of 1.77% and Operating profit at 14.40% over the last 5 years

Flat results in Sep 25

NET SALES(9M) At CNY 1,086.63 MM has Grown at -9.89%
NET PROFIT(9M) At CNY 103.24 MM has Grown at -23.03%
ROCE(HY) Lowest at 2.04%

With ROE of 2.25%, it has a expensive valuation with a 3.05 Price to Book Value

Over the past year, while the stock has generated a return of 28.30%, its profits have fallen by -40.8%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vcanbio Cell & Gene Engineering Corp., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Vcanbio Cell & Gene Engineering Corp., Ltd.

47.35%

1.49

40.33%

China Shanghai Composite

13.33%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.77%

EBIT Growth (5y)

14.40%

EBIT to Interest (avg)

76.71

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.42

Sales to Capital Employed (avg)

0.42

Tax Ratio

32.68%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

4.85%

ROE (avg)

2.55%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

135

Industry P/E

Price to Book Value

3.05

EV to EBIT

83.78

EV to EBITDA

35.27

EV to Capital Employed

4.58

EV to Sales

6.46

PEG Ratio

Dividend Yield

ROCE (Latest)

5.47%

ROE (Latest)

2.25%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 339.03 MM

RAW MATERIAL COST(Y)

Fallen by -7.6% (YoY

CASH AND EQV(HY)

Highest at CNY 3,265.48 MM

DEBT-EQUITY RATIO (HY)

Lowest at -42.87 %

PRE-TAX PROFIT(Q)

At CNY 63.4 MM has Grown at 84.12%

NET PROFIT(Q)

At CNY 48.07 MM has Grown at 93.04%

EPS(Q)

Highest at CNY 0.11

-8What is not working for the Company

NET SALES(9M)

At CNY 1,086.63 MM has Grown at -9.89%

NET PROFIT(9M)

At CNY 103.24 MM has Grown at -23.03%

ROCE(HY)

Lowest at 2.04%

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.11 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.25 times

Here's what is working for Vcanbio Cell & Gene Engineering Corp., Ltd.

Operating Cash Flow

Highest at CNY 339.03 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Pre-Tax Profit

At CNY 63.4 MM has Grown at 84.12%

over average net sales of the previous four periods of CNY 34.43 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 48.07 MM has Grown at 93.04%

over average net sales of the previous four periods of CNY 24.9 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.11

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Cash and Eqv

Highest at CNY 3,265.48 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -42.87 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -7.6% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Vcanbio Cell & Gene Engineering Corp., Ltd.

Net Sales

At CNY 1,086.63 MM has Grown at -9.89%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Inventory Turnover Ratio

Lowest at 2.11 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 2.25 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio